Please Wait
Applying Filters...
menu
    • menu
    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Your reliable CDMO partner - agile, scalable, top-quality Small Molecule API & HPAPI solutions from concept to market

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of peptides and oligonucleotides.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Relebactam anhydrous

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 51,875Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Merck defends antibiotic's approval from 2019
    Merck defends antibiotic's approval from 2019

    17 May 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/merck-defends-antibiotics-approval-from-2019-as-bmj-investigation-points-to-decline-in-fda-standards/

    Zachary Brennan ENDPTS
    17 May 2023
    Share Share
    FDA approvals roundup: Recarbrio
    FDA approvals roundup: Recarbrio

    10 Jun 2020

    // Renee Matthews RAPS

    https://www.raps.org/news-and-articles/news-articles/2020/6/fda-approvals-roundup-recarbrio

    Renee Matthews RAPS
    10 Jun 2020
    Share Share
    US FDA approves Recarbrio to treat hospital-acquired bacterial pneumonia
    US FDA approves Recarbrio to treat hospital-acquired bacterial pneumonia

    07 Jun 2020

    // PHARMABIZ

    http://pharmabiz.com/NewsDetails.aspx?aid=126651&sid=2

    PHARMABIZ
    07 Jun 2020
    Share Share
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment
    FDA Approves Merck’s (imipenem, cilastatin, and relebactam) for the Treatment

    05 Jun 2020

    // MERCK

    https://investors.merck.com/news/press-release-details/2020/FDA-Approves-Mercks-RECARBRIO-imipenem-cilastatin-and-relebactam-for-the-Treatment-of-Adults-with-Hospital-Acquired-and-Ventilator-Associated-Bacterial-Pneumonia-HABPVABP/default.aspx

    MERCK
    05 Jun 2020
    Share Share
    Results of Ph 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™
    Results of Ph 3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™

    06 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200506005158/en

    BUSINESSWIRE
    06 May 2020
    Share Share
    Results of Ph3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™
    Results of Ph3 Trial Evaluating the Efficacy and Safety of Merck’s RECARBRIO™

    05 May 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200506005158/en/Results-Phase-3-Trial-Evaluating-Efficacy-Safety

    BUSINESSWIRE
    05 May 2020
    Share Share